Analyst Reco. Moderna, Inc.

Equities

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-10 pm EST			Pre-market 08:26:55 am
42.00 ^USD	+0.11%		38.05	-9.39%

07:21am	Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010	CI
06:18am	North American Morning Briefing : Futures Mostly Decline; Investors Wait for Jobs Data	DJ

Analyst Reco.

02:39am	Moderna shares fall as FDA declines to review new flu vaccine	RE
Jan. 30	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
Jan. 29	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
Jan. 28	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
Jan. 23	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
Jan. 23	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
Jan. 12	Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating	MT
Jan. 07	UBS Downgrades Moderna to Neutral From Buy, Cuts Price Target to $34 From $40	MT
Jan. 06	BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating	MT
Dec. 12	Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating	MT
Dec. 12	Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target	MT
Nov. 26	Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating	MT
Nov. 21	Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating	MT
Nov. 21	Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating	MT
Nov. 21	RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating	MT
Nov. 21	Wolfe Research Adjusts Price Target on Moderna to $17 From $16, Maintains Underperform Rating	MT
Nov. 21	Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix…
Nov. 17	Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating	MT
Nov. 11	Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says	MT
Nov. 11	Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating	MT
Nov. 07	Leerink Partners Adjusts Moderna Price Target to $15 From $12	MT
Nov. 07	Moderna Continues to Target Cash Breakeven in 2028, Morgan Stanley Says	MT
Nov. 07	Barclays Adjusts Price Target on Moderna to $25 From $31, Maintains Equalweight Rating	MT
Nov. 07	Goldman Sachs Adjusts Price Target on Moderna to $33 From $34, Maintains Neutral Rating	MT
Nov. 07	America's markets lose their nerve

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Moderna Falls As FDA Vows To Impose New Vaccine Rules

December 01, 2025 at 03:32 pm EST

Phenomenal Value Destruction at Moderna

November 24, 2025 at 08:44 am EST